ORGS (Orgenesis) GF Value : $0.35 (As of Jul. 11, 2025)

View and export this data going back to 2010. Start your Free Trial

What is Orgenesis GF Value?

As of today (2025-07-11), Orgenesis's share price is $1.07. Orgenesis's GF Value is $0.35. Therefore, Orgenesis's Price-to-GF-Value for today is 3.06. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Orgenesis is Significantly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Orgenesis (OTCPK:ORGS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (1)
Possible Value Trap, Think Twice	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (2)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (2)	Predictable High Quality Companies which are Significantly Undervalued

(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(2) A sufficient margin of safety exists only when the stock is undervalued.

Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.

Indicators that a company may be a value trap include:

    * Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score.
    * Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials.
    * Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.

Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.

Orgenesis's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.07	/	0.35
	=	3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis GF Value Related Terms

Thank you for viewing the detailed overview of Orgenesis's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (OTCPK:ORGS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Executives

Jacob Safier	10 percent owner	C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Elliot Maltz	officer: Chief Financial Officer	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Efrat Assa Kunik	officer: Chief Development Officer	C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips	director	C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber	officer: Chief Scientific Officer	17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin	director	7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler	director	4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan	officer: CEO	20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles	10 percent owner	AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger	10 percent owner	DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret	officer: See Remarks	48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda	director	2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452